NF-κB signaling in inflammation

Signal Transduction and Targeted Therapy

Volumn 2, Issue , 2017, Pages

  Liu, Ting ^a   Zhang, Lingyun ^a   Joo, Donghyun ^a   Sun, Shao Cong ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85064627519     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/sigtrans.2017.23     Document Type: Review

References (137)

1. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009; 1: a000034.
2. Sun SC, Chang JH, Jin J. Regulation of nuclear factor-kappaB in autoimmunity. Trends Immunol 2013; 34: 282–289.
3. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21: 71–85.
4. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004; 382: 393–409.
5. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693–733.
6. Zhang H, Sun SC. NF-kappaB in inflammation and renal diseases. Cell Biosci 2015; 5: 63.
7. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000; 12: 85–98.
8. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol 2008; 29: 469–478.
9. Israel A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2010; 2: a000158.
10. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344–362.
11. Sun SC. The noncanonical NF-kappaB pathway. Immunol Rev 2012; 246: 125–140.
12. Sun SC, Liu ZG. A special issue on NF-kappaB signaling and function. Cell Res 2011; 21: 1–2.
13. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001; 7: 401–409.
14. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G et al. Activation by IKK alpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001; 293: 1495–1499.
15. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651.
16. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7–11.
17. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci 2014; 1319: 82–95.
18. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 2012; 4: a006049.
19. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240–273.
20. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805–820.
21. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16–34.
22. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109: S81–S96.
23. Hayden MS, Ghosh S. NF-kappaB in immunobiology. Cell Res 2011; 21: 223–244.
24. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145–151.
25. Gohda J, Matsumura T, Inoue J. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling. J Immunol 2004; 173: 2913–2917.
26. Hu H, Sun SC. Ubiquitin signaling in immune responses. Cell Res 2016; 26: 457–483.
27. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005; 6: 1087–1095.
28. Murphy KM. Janeway’s Immunobiology, 8th edn. Garland, 2010.
29. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010; 327: 1098–1102.
30. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 2014; 5: 614.
31. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787–795.
32. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209–212.
33. Yu M, Zhou H, Zhao J, Xiao N, Roychowdhury S, Schmitt D et al. MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J Exp Med 2014; 211: 887–907.
34. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373–384.
35. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13: 460–469.
36. Chang M, Jin W, Sun SC. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol 2009; 10: 1089–1095.
37. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28: 445–489.
38. Oh H, Ghosh S. NF-kappaB: roles and regulation in different CD4(+) T-cell subsets. Immunol Rev 2013; 252: 41–51.
39. Chang M, Jin W, Chang JH, Xiao Y, Brittain GC, Yu J et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol 2011; 12: 1002–1009.
40. Aronica MA, Mora AL, Mitchell DB, Finn PW, Johnson JE, Sheller JR et al. Preferential role for NF-kappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol 1999; 163: 5116–5124.
41. Hilliard BA, Mason N, Xu L, Sun J, Lamhamedi-Cherradi SE, Liou HC et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002; 110: 843–850.
42. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001; 2: 45–50.
43. Chang M, Lee AJ, Fitzpatrick L, Zhang M, Sun SC. NF-kappa B1 p105 regulates T cell homeostasis and prevents chronic inflammation. J Immunol 2009; 182: 3131–3138.
44. Greve B, Weissert R, Hamdi N, Bettelli E, Sobel RA, Coyle A et al. IkappaB kinase 2/beta deficiency controls expansion of autoreactive T cells and suppresses experimental autoimmune encephalomyelitis. JImmunol2007; 179: 179–185.
45. Chen G, Hardy K, Bunting K, Daley S, Ma L, Shannon MF. Regulation of the IL-21 gene by the NF-kappaB transcription factor c-Rel. J Immunol 2010; 185: 2350–2359.
46. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531–564.
47. Shi JH, Sun SC. TCR signaling to NF-kappaB and mTORC1: expanding roles of the CARMA1 complex. Mol Immunol 2015; 68: 546–557.
48. Long M, Park SG, Strickland I, Hayden MS, Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009; 31: 921–931.
49. Ruan Q, Kameswaran V, Tone Y, Li L, Liou HC, Greene MI et al. Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity 2009; 31: 932–940.
50. Chang JH, Xiao Y, Hu H, Jin J, Yu J, Zhou X et al. Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like T cells. Nat Immunol 2012; 13: 481–490.
51. Murray SE, Polesso F, Rowe AM, Basak S, Koguchi Y, Toren KG et al. NF-kappaB-inducing kinase plays an essential T cell-intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J Clin Invest 2011; 121: 4775–4786.
52. Li Y, Wang H, Zhou X, Xie X, Chen X, Jie Z et al. Cell intrinsic role of NF-kappaB-inducing kinase in regulating T cell-mediated immune and autoimmune responses. Sci Rep 2016; 6: 22115.
53. Yu J, Wang Y, Yan F, Zhang P, Li H, Zhao H et al. Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol 2014; 193: 2574–2586.
54. Rowe AM, Murray SE, Raue HP, Koguchi Y, Slifka MK, Parker DC. A cell-intrinsic requirement for NF-kappaB-inducing kinase in CD4 and CD8 T cell memory. J Immunol 2013; 191: 3663–3672.
55. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9: 271–285.
56. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 2016; 16: 407–420.
57. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821–832.
58. de Zoete MR, Palm NW, Zhu S, Flavell RA. Inflammasomes. Cold Spring Harb Perspect Biol 2014; 6: a016287.
59. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015; 21: 677–687.
60. Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev 2015; 265: 6–21.
61. He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 2016; 41: 1012–1021.
62. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 2012; 287: 36617–36622.
63. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013; 49: 331–338.
64. Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol 2015; 25: 308–315.
65. Qiao Y, Wang P, Qi J, Zhang L, Gao C. TLR-induced NF-kappaB activation regulates NLRP3 expression in murine macrophages. FEBS Lett 2012; 586: 1022–1026.
66. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183: 787–791.
67. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKK beta. Cell 2007; 130: 918–931.
68. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J et al. NF-kappaB restricts inflammasome activation via elimination of damaged mitochondria. Cell 2016; 164: 896–910.
69. Criollo A, Senovilla L, Authier H, Maiuri MC, Morselli E, Vitale I et al. The IKK complex contributes to the induction of autophagy. EMBO J 2010; 29: 619–631.
70. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012; 13: 255–263.
71. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221–225.
72. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12: 222–230.
73. Pai S, Thomas R. Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity. J Autoimmun 2008; 31: 245–251.
74. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205–2219.
75. Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High DNA-binding activity of transcription factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 1995; 37: 827–832.
76. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996; 39: 583–591.
77. Gilston V, Jones HW, Soo CC, Coumbe A, Blades S, Kaltschmidt C et al. NF-kappa B activation in human knee-joint synovial tissue during the early stage of joint inflammation. Biochem Soc Trans 1997; 25: 518S.
78. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. Am J Pathol 1998; 152: 793–803.
79. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998; 28: 197–208.
80. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998; 95: 13859–13864.
81. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671–15676.
82. Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897–1907.
83. Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011; 43: 908–912.
84. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology 2008; 47: 584–590.
85. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163–196.
86. Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology 2013; 52: 590–598.
87. Novack DV. Role of NF-kappaB in the skeleton. Cell Res 2011; 21: 169–182.
88. Yao Z, Xing L, Boyce BF. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest 2009; 119: 3024–3034.
89. Baum R, Gravallese EM. Bone as a target organ in rheumatic disease: impact on osteoclasts and osteoblasts. Clin Rev Allergy Immunol 2016; 51: 1–15.
90. Mellado M, Martinez-Munoz L, Cascio G, Lucas P, Pablos JL, Rodriguez-Frade JM. T cell migration in rheumatoid arthritis. Front Immunol 2015; 6: 384.
91. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337–348.
92. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21: 719–729.
93. Wei F, Chang Y, Wei W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine 2015; 76: 537–544.
94. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066–2078.
95. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20: 6–21.
96. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357–369.
97. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42: 477–484.
98. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35–45.
99. Glas J, Torok HP, Tonenchi L, Muller-Myhsok B, Mussack T, Wetzke M et al. Role of the NFKB1-94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Inflamm Bowel Dis 2006; 12: 606–611.
100. Kaustio M, Haapaniemi E, Goos H, Hautala T, Park G, Syrjanen J et al. Damaging heterozygous mutations in NFKB1 lead to diverse immunological phenotypes. J Allergy Clin Immunol 2017, e-pub ahead of print 21 January 2017; doi:10.1016/j. jaci.2016.10.054.
101. Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JM et al. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 2006; 116: 3042–3049.
102. Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 2007; 204: 1475–1485.
103. Vereecke L, Vieira-Silva S, Billiet T, van Es JH, Mc Guire C, Slowicka K et al. A20 controls intestinal homeostasis through cell-specific activities. Nat Commun 2014; 5: 5103.
104. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998–1004.
105. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A. Treatment of murine Th1-and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115: 3057–3071.
106. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285–296.
107. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446: 557–561.
108. Zaph C, Troy AE, Taylor BC, Berman-Booty LD, Guild KJ, Du Y et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007; 446: 552–556.
109. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9: 393–407.
110. Hussman JP, Beecham AH, Schmidt M, Martin ER, McCauley JL, Vance JM et al. GWAS analysis implicates NF-kappaB-mediated induction of inflammatory T cells in multiple sclerosis. Genes Immun 2016; 17: 305–312.
111. International Multiple Sclerosis Genetics, C Genetics, Consortium, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353–1360.
112. Miterski B, Bohringer S, Klein W, Sindern E, Haupts M, Schimrigk S et al. Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun 2002; 3: 211–219.
113. Mc Guire C, Prinz M, Beyaert R, van Loo G. Nuclear factor kappa B (NF-kappaB) in multiple sclerosis pathology. Trends Mol Med 2013; 19: 604–613.
114. Brustle A, Brenner D, Knobbe CB, Lang PA, Virtanen C, Hershenfield BM et al. The NF-kappaB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest 2012; 122: 4698–4709.
115. Molinero LL, Cubre A, Mora-Solano C, Wang Y, Alegre ML. T cell receptor/ CARMA1/NF-kappaB signaling controls T-helper (Th) 17 differentiation. Proc Natl Acad Sci USA 2012; 109: 18529–18534.
116. Mc Guire C, Wieghofer P, Elton L, Muylaert D, Prinz M, Beyaert R et al. Para-caspase MALT1 deficiency protects mice from autoimmune-mediated demyeli-nation. J Immunol 2013; 190: 2896–2903.
117. Ruan Q, Kameswaran V, Zhang Y, Zheng S, Sun J, Wang J et al. The Th17 immune response is controlled by the Rel-RORgamma-RORgamma T transcriptional axis. J Exp Med 2011; 208: 2321–2333.
118. Chen G, Hardy K, Pagler E, Ma L, Lee S, Gerondakis S et al. The NF-kappaB transcription factor c-Rel is required for Th17 effector cell development in experimental autoimmune encephalomyelitis. J Immunol 2011; 187: 4483–4491.
119. Hofmann J, Mair F, Greter M, Schmidt-Supprian M, Becher B. NIK signaling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses. J Exp Med 2011; 208: 1917–1929.
120. Jin W, Zhou XF, Yu J, Cheng X, Sun SC. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood 2009; 113: 6603–6610.
121. Ellrichmann G, Thone J, Lee DH, Rupec RA, Gold R, Linker RA. Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. J Neuroinflammation 2012; 9: 15.
122. Lee MJ, Bing SJ, Choi J, Jang M, Lee G, Lee H et al. IKKbeta-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1/Th17 cell activation and compromising blood brain barrier. Mol Neurodegener 2016; 11: 54.
123. van Loo G, De Lorenzi R, Schmidt H, Huth M, Mildner A, Schmidt-Supprian M et al. Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol 2006; 7: 954–961.
124. Brambilla R, Dvoriantchikova G, Barakat D, Ivanov D, Bethea JR, Shestopalov VI. Transgenic inhibition of astroglial NF-kappaB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis. J Neuroinflammation 2012; 9: 213.
125. Brambilla R, Persaud T, Hu X, Karmally S, Shestopalov VI, Dvoriantchikova G et al. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J Immunol 2009; 182: 2628–2640.
126. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317–325.
127. Yu XH, Zheng XL, Tang CK. Nuclear factor-kappaB activation as a pathological mechanism of lipid metabolism and atherosclerosis. Adv Clin Chem 2015; 70: 1–30.
128. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004; 101: 5634–5639.
129. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R et al. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab 2008; 8: 372–383.
130. Kempe S, Kestler H, Lasar A, Wirth T. NF-kappaB controls the global proinflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 2005; 33: 5308–5319.
131. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61: 671–682.
132. Ferreira V, van Dijk KW, Groen AK, Vos RM, van der Kaa J, Gijbels MJ et al. Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis 2007; 192: 283–290.
133. Goossens P, Vergouwe MN, Gijbels MJ, Curfs DM, van Woezik JH, Hoeksema MA et al. Myeloid IkappaBalpha deficiency promotes atherogenesis by enhancing leukocyte recruitment to the plaques. PLoS One 2011; 6: e22327.
134. Park SH, Sui Y, Gizard F, Xu J, Rios-Pilier J, Helsley RN et al. Myeloid-specific IkappaB kinase beta deficiency decreases atherosclerosis in low-density lipo-protein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2012; 32: 2869–2876.
135. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003; 112: 1176–1185.
136. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010; 14: 45–55.
137. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77–80.